A Borghetti1, G Baldin1, F Lombardi1, A Ciccullo1, A Capetti2, S Rusconi3, G Sterrantino4, A Latini5, M V Cossu2, R Gagliardini6, A De Luca6, S Di Giambenedetto1. 1. Institute of Clinical Infectious Disease, Catholic University of the Sacred Heart, Rome, Italy. 2. Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy. 3. Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy. 4. Division of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence, Italy. 5. Infectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome, Italy. 6. University Division of Infectious Diseases, Siena University Hospital, Siena, Italy.
Abstract
OBJECTIVES: We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA. METHODS: Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 infected patients, starting lamivudine + dolutegravir after reaching viral suppression. Secondary objective was the evaluation of changes in lipid profile, renal and immunological functions at week 48. RESULTS: We enrolled 206 patients (72.8% male, with 51 years median age), who mainly switched their antiretroviral therapy for simplification (32.5%) or drug toxicity (54.5%). The estimated probability of maintaining virological suppression at 48 and 96 weeks was 98.2% and 95.1%, respectively. VF was independently predicted by cumulative time on antiretroviral therapy. The estimated probability of remaining on lamivudine plus dolutegravir was 86.7% and 80.5% at week 48 and 96, respectively. A significant improvement in immunological function (CD4 count and CD4/CD8 ratio) was evidenced at week 48, as well as a decrease in total cholesterol/HDL ratio, triglycerides and estimated glomerular filtration rate. CONCLUSIONS: Lamivudine plus dolutegravir was effective in maintaining viral suppression in our cohort and led to an improvement in metabolic and immunologic functions.
OBJECTIVES: We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA. METHODS: Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 infectedpatients, starting lamivudine + dolutegravir after reaching viral suppression. Secondary objective was the evaluation of changes in lipid profile, renal and immunological functions at week 48. RESULTS: We enrolled 206 patients (72.8% male, with 51 years median age), who mainly switched their antiretroviral therapy for simplification (32.5%) or drug toxicity (54.5%). The estimated probability of maintaining virological suppression at 48 and 96 weeks was 98.2% and 95.1%, respectively. VF was independently predicted by cumulative time on antiretroviral therapy. The estimated probability of remaining on lamivudine plus dolutegravir was 86.7% and 80.5% at week 48 and 96, respectively. A significant improvement in immunological function (CD4 count and CD4/CD8 ratio) was evidenced at week 48, as well as a decrease in total cholesterol/HDL ratio, triglycerides and estimated glomerular filtration rate. CONCLUSIONS:Lamivudine plus dolutegravir was effective in maintaining viral suppression in our cohort and led to an improvement in metabolic and immunologic functions.
Authors: Leah H Rubin; Jane A O'Halloran; Dionna W Williams; Yuliang Li; Kathryn C Fitzgerald; Raha Dastgheyb; Alexandra L Damron; Pauline M Maki; Amanda B Spence; Anjali Sharma; Deborah R Gustafson; Joel Milam; Kathleen M Weber; Adaora A Adimora; Igho Ofotokun; Margaret A Fischl; Deborah Konkle-Parker; Yanxun Xu Journal: J Neuroimmune Pharmacol Date: 2022-02-17 Impact factor: 7.285
Authors: Neha Sheth Pandit; Daniel B Chastain; Andrea M Pallotta; Melissa E Badowski; Emily C Huesgen; Sarah M Michienzi Journal: Curr Infect Dis Rep Date: 2019-09-07 Impact factor: 3.725
Authors: Jonathan Z Li; Paul E Sax; Vincent C Marconi; Jesse Fajnzylber; Baiba Berzins; Amesika N Nyaku; Carl J Fichtenbaum; Timothy Wilkin; Constance A Benson; Susan L Koletar; Ramon Lorenzo-Redondo; Babafemi O Taiwo Journal: Open Forum Infect Dis Date: 2019-02-11 Impact factor: 3.835
Authors: Soo-Yon Rhee; Philip M Grant; Philip L Tzou; Geoffrey Barrow; P Richard Harrigan; John P A Ioannidis; Robert W Shafer Journal: J Antimicrob Chemother Date: 2019-11-01 Impact factor: 5.790